Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Dec 2;2014(12):CD010623.
doi: 10.1002/14651858.CD010623.pub2.

Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions

Huan Song  1 , Jianwei Zhu, DongHao Lu
Affiliations
Meta-Analysis

Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions

Huan Song et al. Cochrane Database Syst Rev. .

Abstract

Background: Proton pump inhibitors (PPIs) are the most effective drugs to reduce gastric acid secretion. PPIs are one of the most commonly prescribed classes of medications worldwide. Apart from short-term application, maintenance therapy with PPIs is recommended and increasingly used in certain diseases, such as Zollinger-Ellison syndrome and gastro-oesophageal reflux disease, especially for people with erosive oesophagitis or Barrett's oesophagus. Although PPIs are generally safe, their efficacy and safety of long-term use remains unclear. The question of whether the long-term use of PPIs could promote the development of gastric pre-malignant lesions has been widely investigated, but results are inconsistent. Limited insight on this problem leads to a dilemma in decision making for long-term PPI prescription.

Objectives: To compare the development or progression of gastric pre-malignant lesions, such as atrophic gastritis, intestinal metaplasia, enterochromaffin-like (ECL) cell hyperplasia, and dysplasia, in people taking long-term (six months or greater) PPI maintenance therapy.

Search methods: We searched the following databases (from inception to 6 August 2013): the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL. In addition, we searched the reference lists of included trials and contacted experts in the field.

Selection criteria: We searched for randomised controlled trials (RCTs) in adults (aged 18 years or greater) concerning the effects of long-term (six months or greater) PPI use on gastric mucosa changes, confirmed by endoscopy or biopsy sampling (or both).

Data collection and analysis: Two review authors independently performed selection of eligible trials, assessment of trial quality, and data extraction. We calculated odds ratios (OR) for analysis of dichotomous data and mean differences for continuous data, with 95% confidence intervals (CI).

Main results: We included seven trials (1789 participants). Four studies had high risk of bias and the risk of bias in the other three trials was unclear. In addition, it was difficult to assess possible reporting bias. We pooled 1070 participants from four RCTs to evaluate corporal atrophy development revealing an insignificantly increased OR of 1.50 (95% CI 0.59 to 3.80; P value = 0.39; low-quality evidence) for long-term PPI users relative to non-PPI users. In five eligible trials, corporal intestinal metaplasia was assessed among 1408 participants, also with uncertain results (OR 1.46; 95% CI 0.43 to 5.03; P value = 0.55; low-quality evidence). However, by pooling data of 1705 participants from six RCTs, our meta-analysis showed that participants with PPI maintenance treatment were more likely to experience either diffuse (simple) (OR 5.01; 95% CI 1.54 to 16.26; P value = 0.007; very-low-quality evidence) or linear/micronodular (focal) ECL hyperplasia (OR 3.98; 95% CI 1.31 to 12.16; P value = 0.02; low-quality evidence) than controls. No participant showed any dysplastic or neoplastic change in any included studies.

Authors' conclusions: There is presently no clear evidence that the long-term use of PPIs can cause or accelerate the progression of corpus gastric atrophy or intestinal metaplasia, although results were imprecise. People with PPI maintenance treatment may have a higher possibility of experiencing either diffuse (simple) or linear/micronodular (focal) ECL cell hyperplasia. However, the clinical importance of this outcome is currently uncertain.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Atrophy (proton pump inhibitor (PPI) versus control), Outcome 1 Number of participants with worsening scores in corporal atrophy.
2.1
2.1. Analysis
Comparison 2 Intestinal metaplasia (proton pump inhibitor (PPI) versus control), Outcome 1 Number of participants with worsening scores in corporal intestinal metaplasia.
3.1
3.1. Analysis
Comparison 3 Enterochromaffin‐like cell hyperplasia (proton pump inhibitor (PPI) versus control), Outcome 1 Increase in number of participants with simple (diffuse) hyperplasia after treatment.
3.2
3.2. Analysis
Comparison 3 Enterochromaffin‐like cell hyperplasia (proton pump inhibitor (PPI) versus control), Outcome 2 Increase in number of participants with linear/micronodular (focal) hyperplasia, comparing final biopsies with baseline biopsies.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010623

References

References to studies included in this review

Dent 1994 {published data only}
    1. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35(5):590‐8. - PMC - PubMed
Fiocca 2012 {published data only}
    1. Fiocca R, Mastracci L, Attwood SE, Ell C, Galmiche JP, Hatlebakk J, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5‐year follow‐up in the LOTUS trial. Alimentary Pharmacology and Therapeutics 2012;36(10):959‐71. - PubMed
Gough 1996 {published data only}
    1. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Alimentary Pharmacology and Therapeutics 1996;10(4):529‐39. - PubMed
Hallerbäck 1994 {published data only}
    1. Hallerbäck B, Unge P, Carling L, Edwin B, Glise H, Havu N, et al. Omeprazole or ranitidine in long‐term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994;107(5):1305‐11. - PubMed
Johnson+Vakil {published data only}
    1. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6‐12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257‐65. - PubMed
Johnson 2001 {published data only}
    1. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6‐12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257‐65. - PubMed
    1. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double‐blind, placebo‐controlled study of efficacy and safety. American Journal of Gastroenterology 2001;96(1):27‐34. - PubMed
Lundell 1999 {published data only}
    1. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999;117(2):319‐26. - PubMed
Vakil 2001 {published data only}
    1. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6‐12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257‐65. - PubMed
    1. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6‐month, randomized, double‐blind, placebo‐controlled study of efficacy and safety. Alimentary Pharmacology and Therapeutics 2001;5(7):927‐35. - PubMed

References to studies excluded from this review

Gardner 1999 {published data only}
    1. Gardner JD, Rindi G, Dayal Y, Fiocca R, Perdomo C, Jaskir J, et al. Evolution of Helicobacter pylori infection, gastritis and enterochromaffine‐like cell hyperplasia in 443 patients with gastroesophageal reflux disease treated for one year with rabeprazole. Gastroenterology 1999;16(4 part 2):G0731.
Lundell 2006 {published data only}
    1. Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, et al. Changes of gastric mucosal architecture during long‐term omeprazole therapy: results of a randomized clinical trial. Alimentary Pharmacology and Therapeutics 2006;23(5):639‐47. - PubMed
Meining 1998 {published data only}
    1. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori‐induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Alimentary Pharmacology and Therapeutics 1998;12(8):735‐40. - PubMed
Nishi 2005 {published data only}
    1. Nishi T, Makuuchi H, Weinstein WM. Changes in gastric ECL cells and parietal cells after long‐term administration of high‐dose omeprazole to patients with Barrett's esophagus. Tokai Journal of Experimental and Clinical Medicine 2005;30(2):117‐21. - PubMed
Richter 2003 {published data only}
    1. Richter J, Fraga P, Mack M, Dermovsesian A. Comparison of the clinical efficacy and safety of pantoprazole vs ranitidin over three years to prevent relapse in patients with healed erosive esophagitis. Gastroenterology 2003;124:A232.

Additional references

Abraham 2012
    1. Abraham NS. Proton pump inhibitors: potential adverse effects. Current Opinion in Gastroenterology 2012;28(6):615‐20. - PubMed
Agrawal 2000
    1. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti‐inflammatory drug‐associated gastric ulcers: results of a double‐blind, randomized, multicenter study. Archives of Internal Medicine 2000;160(10):1455‐61. - PubMed
Ali 2009
    1. Ali T, Roberts DN, Tierney WM. Long‐term safety concerns with proton pump inhibitors. American Journal of Medicine 2009;112(10):896‐903. - PubMed
Anderson 2010
    1. Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS. Age‐specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010;303(17):1723‐8. - PMC - PubMed
Asfeldt 2008
    1. Asfeldt AM, Straume B, Steigen SE, Løchen ML, Florholmen J, Bernersen B, et al. Changes in the prevalence of dyspepsia and Helicobacter pylori infection after 17 years: the Sørreisa gastrointestinal disorder study. European Journal of Epidemiology 2008;23(9):625‐33. - PubMed
Borenstein 2008
    1. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta‐Analysis (Statistics in Practice). Chichester: John Wiley & Sons, 2008.
Brunner 2012
    1. Brunner G, Athmann C, Schneider A. Long‐term, open‐label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid‐peptic disease. Alimentary Pharmacology & Therapeutics 2012;36(1):37‐47. - PubMed
Cooper 2006
    1. Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Alimentary Pharmacology & Therapeutics 2006;23(6):727‐33. - PubMed
Correa 1992
    1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process ‐ First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Research 1992;52(24):6735‐40. - PubMed
Dajani 2000
    1. Dajani EZ. Gastroesophageal reflux disease: pathophysiology and pharmacology overview. Journal of the Association for Academic Minority Physicians 2000;11(1):7‐11. - PubMed
Dekkers 1999
    1. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Alimentary Pharmacology and Therapeutics 1999;13(2):179‐86. - PubMed
Dinis‐Ribeiro 2011
    1. Dinis‐Ribeiro M, Areia M, Vries AC, Marcos‐Pinto R, Monteiro‐Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2011;44(1):74‐94. - PMC - PubMed
Dixon 1996
    1. Dixon MF, Genta RM, Yardley JH. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. American Journal of Surgical Pathology 1996;20:1161‐81. - PubMed
Eissele 1997
    1. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997;112(3):707‐17. - PubMed
Eslami 2013
    1. Eslami L, Nasseri‐Moghaddam S. Meta‐analyses: does long‐term PPI use increase the risk of gastric premalignant lesions?. Archives of Iranian Medicine 2013;16(8):449‐58. - PubMed
Ferlay 2010
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010;127(12):2893‐917. - PubMed
Ficoca 2010
    1. Fiocca R, Mastracci L, Attwood S, Ell C, Galmiche J, Hatlebakk J, et al. Exocrine and endocrine gastric mucosal changes under medical or surgical antireflux therapy. Results of a 5‐yr follow up in the lotus trial. Gastroenterology 2010;138(5):S649‐50.
Fox 2011
    1. Fox JG, Kuipers EJ. Long‐term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil. Gut 2011;60(5):567‐8. - PMC - PubMed
Freston 1994
    1. Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Annals of Internal Medicine 1994;121(3):232‐3. - PubMed
Fukao 1993
    1. Fukao A, Hisamichi S, Ohsato N, Fujino N, Endo N, Iha M. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control 1993;4(1):17‐20. - PubMed
Geboes 2001
    1. Geboes K, Dekker W, Mulder CJ, Nusteling K, Dutch Study Group. Long‐term lansoprazole treatment for gastro‐oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Alimentary Pharmacology and Therapeutics 2001;15(11):1819‐26. - PubMed
Genta 1998
    1. Genta RM. Review article: gastric atrophy and atrophic gastritis ‐ nebulous concepts in search of a definition. Alimentary Pharmacology and Therapeutics 1998;12(Suppl 1):17‐23. - PubMed
Genta 2003
    1. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6‐12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257‐65. - PubMed
GRADEprofiler 2008 [Computer program]
    1. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEprofiler (GRADEpro). Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
Haag 2003
    1. Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Endoscopy 2003;35(2):112‐7. - PubMed
Hassall 2011
    1. Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El‐Serag H. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell‐like hyperplasia. Alimentary Pharmacology and Therapeutics 2011;33(7):829‐36. - PubMed
Held 2004
    1. Held M. Epidemiological Studies of Helicobacter pylori and its Relation to Cancer and Precancerous Lesions in the Upper Gastrointestinal Tract. Stockholm: Karolinska Institutet, 2004.
Hetzel 1988
    1. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95(4):903‐12. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Holt 1991
    1. Holt S, Howden CW. Omeprazole: overview and opinion. Digestive Diseases and Sciences 1991;36(4):385‐93. - PubMed
Horwhat 2007
    1. Horwhat JD, Baroni D, Maydonovitch C, Osgard E, Ormseth E, Rueda‐Pedraza E, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. American Journal of Gastroenterology 2007;102(3):497‐506. - PubMed
Hwang 2006
    1. Hwang JH, Rulyak SD, Kimmey MB. American Gastroenterological Association Institute technical review on the management of gastric subepithelial masses. Gastroenterology 2006;130(7):2217‐28. - PubMed
Jianu 2012
    1. Jianu CS, Fossmark R, Viset T, Qvigstad G, Sørdal O, Mårvik R, et al. Gastric carcinoids after long‐term use of a proton pump inhibitor. Alimentary Pharmacology & Therapeutics 2012;31(7):644‐9. - PubMed
Johnson 2013
    1. Johnson DA, Oldfield EC 4th. Reported side effects and complications of long‐term proton pump inhibitor use: dissecting the evidence. Clinical Gastroenterology and Hepatology 2013;11(5):458‐64. - PubMed
Kader 1998
    1. Kader SA, Mansour AM, Mohran Z, el‐Taoil A, Abdalla KF. A study on the relation between proton pump inhibitor and gastric giardiasis. Journal of the Egyptian Society of Parasitology 1998;28(1):149‐57. - PubMed
Kapadia 2003
    1. Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. Journal of Clinical Gastroenterology 2003;36(5 Suppl):S29‐36, S61‐2. - PubMed
Klinkenberg‐Knol 2000
    1. Klinkenberg‐Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long‐term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118(4):661‐9. - PubMed
Kuipers 1996
    1. Kuipers EJ, Lundell L, Klinkenberg‐Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. New England Journal of Medicine 1996;334(16):1018‐22. - PubMed
Kuipers 2004
    1. Kuipers EJ, Nelis GF, Klinkenberg‐Knol EC, Snel P, Goldfain D, Kolkman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53(1):12‐20. - PMC - PubMed
Laheij 2004
    1. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community‐acquired pneumonia and use of gastric acid‐suppressive drugs. JAMA 2004;292(16):1955‐60. - PubMed
Laine 2000
    1. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors. Alimentary Pharmacology and Therapeutics 2000;14(6):651‐68. - PubMed
Lamberts 2001
    1. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001;64(4):205‐13. - PubMed
Lauren 1965
    1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so‐called intestinal‐type carcinoma. Acta Pathologica et Microbiologica Scandinavica 1965;64:31‐49. - PubMed
Lee 1996
    1. Lee SW, Lieberman DA, Ippoliti AD, Hsieh CY, Weinstein WM. Changes in the parietal cell mass after long‐term therapy with high dose omeprazole in Barrett's esophagus (BE). Gastroenterology 1996;110:A173.
Malfertheiner 2007
    1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El‐Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56(6):772‐81. - PMC - PubMed
Marks 1994
    1. Marks RD, Richter JE, Rizzo J. Omeprazole vs. H2‐receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106(4):907‐15. - PubMed
McColl 2000
    1. McColl KEL, Murray LS, Gillen D. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:239. - PubMed
Moayyedi 2000
    1. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, et al. Changing patterns of Helicobacter pylori gastritis in long‐standing acid suppression. Helicobacter 2000;5(4):206‐14. - PubMed
Neal 1996
    1. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case‐control study. BMJ 1996;312(7028):414‐5. - PMC - PubMed
Norton 1999
    1. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger‐Ellison syndrome. New England Journal of Medicine 1999;341(9):635‐44. - PubMed
Peters 1999
    1. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg‐Knol EC, Lamers CB, et al. Endoscopic regression of Barrett's oesophagus during omeprazole therapy. Gut 1999;45(4):489‐94. - PMC - PubMed
Pounder 2000
    1. Pounder RE, Williams MP. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:238‐9. - PubMed
Poynard 1995
    1. Poynard T, Lemaire M, Agostini H. Meta‐analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. European Journal of Gastroenterology and Hepatology 1995;7(7):661‐5. - PubMed
Price 1991
    1. Price AB. The Sydney System: histological division. Journal of Gastroenterology and Hepatology 1991;6(3):209‐22. - PubMed
RevMan 2013 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Reynaert 1995
    1. Reynaert H, Fernandes E, Bourgain C, Smekens L, Devis G. Proton‐pump inhibition and gastric giardiasis: a causal or casual association?. Journal of Gastroenterology 1995;30(6):775‐8. - PubMed
Richter 2000
    1. Richter J, Kahrilas P, Hwang C, Marino V, Hamelin B. Six month safety and tolerability of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (EE). Gastroenterology 2000;118(4 part 2):A1299.
Rindi 2005
    1. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B, European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. European Journal of Gastroenterology and Hepatology 2005;17(5):559‐66. - PubMed
Rostom 2002
    1. Rostom A, Dube C, Wells GA, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID‐induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002296] - DOI - PubMed
Sanduleanu 1999
    1. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium‐ and long‐term acid suppressive therapy: a case‐control study. Alimentary Pharmacology and Therapeutics 1999;13(2):145‐53. - PubMed
Sanduleanu 2001
    1. Sanduleanu S, Jonkers D, De Bruïne A, Hameeteman W, Stockbrügger RW. Double gastric infection with Helicobacter pylori and non‐Helicobacter pylori bacteria during acid‐suppressive therapy: increase of pro‐inflammatory cytokines and development of atrophic gastritis. Alimentary Pharmacology and Therapeutics 2001;15(8):1163‐75. - PubMed
Schenk 1998
    1. Schenk BE, Kuipers EJ, Klinkenberg‐Knol EC, Bloemena E, Nelis GF, Festen HP, et al. Hypergastrinaemia during long‐term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 1998;12(7):605‐12. - PubMed
Schenk 2000
    1. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46(5):615‐21. - PMC - PubMed
Shiota 2013
    1. Shiota S, Murakawi K, Suzuki R, Fujioka T, Yamaoka Y. Helicobacter pylori infection in Japan. Expert Review of Gastroenterology and Hepatology 2013;7(1):35‐40. - PMC - PubMed
Sipponen 2007
    1. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scandinavian Journal of Gastroenterology 2007;42(1):2‐10. - PubMed
Solcia 1988
    1. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988;41(4):185‐200. - PubMed
Solcia 1995
    1. Solcia E, Fiocca R, Villani L, Luinetti O, Capella C. Hyperplastic, dysplastic, and neoplastic enterochromaffin‐like‐cell proliferations of the gastric mucosa. Classification and histogenesis. American Journal of Surgical Pathology 1995;19(Suppl 1):S1‐7. - PubMed
Suzuki 2008
    1. Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. Journal of Clinical Biochemistry and Nutrition 2008;42(2):71‐5. - PMC - PubMed
Thomson 2010
    1. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long‐term use of proton pump inhibitors. World Journal of Gastroenterology 2010;16(19):2323‐30. - PMC - PubMed
Uemura 2000
    1. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Mashiba H, et al. Changes in Helicobacter pylori‐induced gastritis in the antrum and corpus during long‐term acid‐suppressive treatment in Japan. Alimentary Pharmacology and Therapeutics 2000;14(10):1345‐52. - PubMed
Vigneri 1995
    1. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. New England Journal of Medicine 1995;333(17):1106‐10. - PubMed
Waldum 2014
    1. Waldum HL, Hauso O, Fossmark R. The regulation of gastric acid secretion ‐ clinical perspectives. Acta Physiologica 2014;210:239‐56. - PubMed
Wilkinson 1999
    1. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar lined Barrett's oesophagus with omeprazole 40 mg daily: results of 5 years continuous therapy. Alimentary Pharmacology and Therapeutics 1999;13(9):1205‐9. - PubMed
Wolfe 2000
    1. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress‐related erosive syndrome. Gastroenterology 2000;118(2 Suppl 1):S9‐31. - PubMed

References to other published versions of this review

Eslami 2008
    1. Eslami L, Kalantarian S, Nasseri‐Moghaddam S, Majdzadeh R. Long term proton pump inhibitor (PPI) use and incidence of gastric (pre) malignant lesions. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD007098.pub2] - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources